← Back to Search

Angiogenesis Inhibitor

Bevacizumab for Endometrial Cancer (Clovis-001 Trial)

Phase 2
Waitlist Available
Led By Kathleen Moore, MD
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 year
Awards & highlights

Clovis-001 Trial Summary

This trial is testing a new combination drug to see how well it works in patients with cervical or endometrial cancer that has come back. The goal is to see if the patients taking the new drug combination survive without their cancer progressing for at least 6 months.

Eligible Conditions
  • Endometrial Cancer
  • Cervical Cancer

Clovis-001 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of Patients Who Are Progression-free at 6 Months
Secondary outcome measures
Median Overall Survival
Median Progression-free Survival Time
Number of Patients Who Experience Toxicity
+1 more

Clovis-001 Trial Design

1Treatment groups
Experimental Treatment
Group I: Bevacizumab + RucaparibExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bevacizumab
2013
Completed Phase 4
~5280
Rucaparib
2016
Completed Phase 3
~1990

Find a Location

Who is running the clinical trial?

University of OklahomaLead Sponsor
455 Previous Clinical Trials
97,564 Total Patients Enrolled
6 Trials studying Endometrial Cancer
292 Patients Enrolled for Endometrial Cancer
Clovis Oncology, Inc.Industry Sponsor
64 Previous Clinical Trials
11,622 Total Patients Enrolled
2 Trials studying Endometrial Cancer
42 Patients Enrolled for Endometrial Cancer
Kathleen Moore, MDPrincipal InvestigatorObstetrics and Gynecology
8 Previous Clinical Trials
396 Total Patients Enrolled
2 Trials studying Endometrial Cancer
149 Patients Enrolled for Endometrial Cancer

Media Library

Bevacizumab (Angiogenesis Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03476798 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How have patients responded to Bevacizumab treatments?

"We have estimated the safety of Bevacizumab to be a 2 on our risk scale, as this is still in Phase 2. While there is some supporting data for its safety, efficacy has yet to be established."

Answered by AI

Are there any vacancies for this research endeavor?

"Recruitment for this trial has concluded. It was initially listed on June 29th, 2018 and the last update was July 13th 2022. For those looking to participate in similar studies, there are currently 518 trials related to endometrial neoplasms and 383 clinical investigations utilizing Bevacizumab actively seeking patients."

Answered by AI

What medical applications is Bevacizumab typically utilized for?

"Bevacizumab has been widely used in treating malignant neoplasms, and it can also be deployed to address recurrent platinum sensitive primary peritoneal cancer, stage iv epithelial ovarian cancer following initial surgical resection, locally advanced nonsquamous non-small cell lung cancer."

Answered by AI

What is the scope of this medical experiment in terms of participants?

"This trial is no longer enrolling participants, having been first posted on June 29th 2018 and last adjusted on July 13th 2022. Nevertheless, there are 518 studies seeking people with endometrial neoplasms and 383 trials recruiting those taking Bevacizumab."

Answered by AI

What other experiments have been conducted to assess the efficacy of Bevacizumab?

"Initially evaluated in 2004 at Memoral Sloan Kettering Basking Ridge, bevacizumab has been subject of 1026 trials. Currently there are 383 studies actively enrolling participants with a significant concentration located in Charlottesville, Virginia."

Answered by AI

Does this medical trial permit geriatric individuals as participants?

"This clinical trial requires participants to be between 18 and 99 years old. For those under 18 or over 65, there are respectively 52 and 848 other trials available."

Answered by AI

Who meets the qualifications for participating in this clinical experiment?

"This research project is searching for 49 participants suffering from endometrial neoplasms, aged between 18 and 99. To be eligible applicants must satisfy the following requirements: histologically-confirmed cervical or endometrial carcinoma; evaluable lesions as characterized by RECIST 1.1 criteria; ECOG performance status of 0 to 2; consent for tumor biopsy (if not feasible other conditions apply); adequate organ function indicated via laboratory tests taken within 14 days prior to administration of rucaparib; have a life expectancy larger than three months; no major existing co-morbidities impeding therapy in view of principal investigator and finally"

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
2018. "Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03476798.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top